Investment Rating - The report maintains a "Strong Buy" rating for Xianle Health, indicating an expectation to outperform the benchmark index by over 20% in the next six months [10]. Core Insights - The company has released its 2025 earnings forecast, projecting a net profit attributable to shareholders between 101 million to 151 million yuan, representing a year-on-year decline of 68.85% to 53.44% [2]. - The company has introduced a 2026 restricted stock incentive plan, granting 2.2025 million shares at a price of 12.21 yuan per share, covering 85 management and core technical personnel [2]. - The company aims to achieve revenue targets of no less than 50.90 billion yuan, 53.83 billion yuan, and 58.32 billion yuan for the years 2026 to 2028, respectively [2]. - The company has also revised its 2023/2025 equity incentive plans, adjusting revenue targets downwards for 2026 [2]. Financial Performance - Total revenue is projected to grow from 4.211 billion yuan in 2024 to 5.536 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 8.8% [10]. - The net profit is expected to recover significantly from 121 million yuan in 2025 to 458 million yuan in 2027, reflecting a growth rate of 19.5% [10]. - The company’s asset-liability ratio stands at 53.22%, indicating a moderate level of financial leverage [5]. Market Position - The global nutrition and health solutions market is expected to grow from 29.4 billion USD in 2024 to 42.4 billion USD by 2029, with a CAGR of 7.6% [11]. - Xianle Health ranks third globally in the nutrition and health food solutions market, holding a 2.0% market share, with notable strengths in gummy and soft capsule segments [9][11]. - The company is well-positioned to capture market share due to its strong R&D capabilities and a robust supply chain [9]. Incentive Plans - The 2026 restricted stock incentive plan aims to align management and technical personnel's performance with company growth, focusing on both revenue and profit targets [2]. - The employee stock ownership plan covers up to 12 core management members, with profit targets set at no less than 3.8 billion yuan for 2026 and 4.5 billion yuan for 2027 [2][21].

Investment Rating - The report maintains an "Increase" rating for the companies involved in the health supplement industry, specifically for Xianle Health and Tongchen Beijian [6]. Core Insights - The health supplement industry is experiencing accelerated development driven by AI applications, enabling personalized and efficient nutrition solutions. Companies are leveraging AI for various functions, including ingredient discovery, formula design, market insights, and compliance verification [2][4]. - Xianle Health is actively integrating AI into its operations, collaborating with DeepSeek to create an AI-driven model for personalized nutrition management, enhancing consumer engagement through tailored health packages [3]. - H&H International Holdings is utilizing AI to provide precise market responses and consumer insights, transitioning from passive treatment to proactive health management [3]. - Tongchen Beijian is exploring AI applications in management and marketing, aiming to strengthen brand presence through innovative advertising strategies [4]. - The report suggests that companies that adopt AI technology early in the health supplement sector will benefit from improved research efficiency, new product development, and market positioning [4]. Summary by Sections AI Empowerment in Health Supplements - AI is transforming the health supplement industry by providing personalized nutrition solutions, optimizing ingredient selection, and enhancing marketing strategies [2][4]. - Companies like Xianle Health and H&H International are at the forefront of this transformation, utilizing AI for consumer insights and product development [3]. Company-Specific Developments - Xianle Health is focusing on AI-driven personalized nutrition, enhancing consumer engagement through tailored health packages [3]. - H&H International is building an AI-enabled service model to better meet consumer health management needs [3]. - Tongchen Beijian is implementing AI in its marketing efforts to strengthen brand recognition and consumer connection [4]. - Jia Biyou is transitioning towards a smart health solution platform, leveraging AI to provide personalized nutrition interventions [4]. Investment Recommendations - The report highlights the potential for significant growth in the health supplement sector driven by AI, recommending investors to focus on companies like Xianle Health, H&H International, Tongchen Beijian, and Jia Biyou for potential investment opportunities [4].

中国上市公司网讯1月29日，港交所官网披露了仙乐健康科技股份有限公司(以下简称"仙乐健康")在港 交所提交的上市申请，公司上市材料被正式受理，独家保荐人为中信证券。 公开数据显示，仙乐健康是领先的营养健康食品解决方案提供商，根据灼识咨询数据按2024年的收入 计，公司于全球营养健康食品解决方案市场占据第三大市场份额，而在中国营养健康食品解决方案市场 则排名第一。此外，根据灼识咨询的资料，按2024年收入计，公司位列全球第二大的软糖及软胶囊营养 健康食品解决方案提供商。立足于潜力巨大的营养健康食品解决方案市场，公司的业务表现实现稳步增 长并保持可持续发展。 公司成立于1993年，随着对健康需求的深入理解，公司的战略重心逐步由制药转向营养健康食品领域， 并在过去33年的蓬勃发展中，公司已建立全面的解决方案组合，覆盖全人群的全品类多剂型产品体系， 并得到跨多种业务模式的多元化客户群的支持。 中国上市公司网讯1月29日，港交所官网披露了仙乐健康科技股份有限公司(以下简称"仙乐健康")在港 交所提交的上市申请，公司上市材料被正式受理，独家保荐人为中信证券。 公开数据显示，仙乐健康是领先的营养健康食品解决方案提供商，根据 ...

Group 1: Profit Forecasts - Dongcai Technology expects a net profit of approximately 300 million yuan for 2025, representing a year-on-year increase of about 65.73% [1] - Aerospace Electronics anticipates a net profit of 192 million to 247 million yuan for 2025, a decrease of 55% to 65% year-on-year [2] - Oulai New Materials forecasts a loss of 33 million to 48 million yuan for 2025, compared to a profit of 28.17 million yuan in the previous year [3] - Jiu Ding New Materials projects a net profit of 85 million to 98 million yuan for 2025, reflecting a year-on-year increase of 187.68% to 231.68% [5] - Chuan Yi Technology expects a net profit of 78 million to 103 million yuan for 2025, reversing a loss of 73.47 million yuan from the previous year [6] - Ju Yi Technology anticipates a net profit of 70 million to 105 million yuan for 2025, representing a year-on-year increase of 228.36% to 392.54% [7] - ST Xifa forecasts a net profit of 110 million to 160 million yuan for 2025, a year-on-year increase of 319.91% to 510.77% [19] - Light Media expects a net profit of approximately 1.5 billion to 1.9 billion yuan for 2025, reflecting a year-on-year increase of 413.67% to 550.65% [34] - Tianqi Lithium anticipates a profit of 369 million to 553 million yuan for 2025, compared to a loss of 7.905 billion yuan in the previous year [31] Group 2: Loss Forecasts - Star Ring Technology expects a loss of 220 million to 250 million yuan for 2025, with a projected revenue of 420 million to 450 million yuan, a year-on-year increase of 13.06% to 21.13% [9] - Filinger anticipates a loss of 65 million to 85 million yuan for 2025, compared to a loss of 37.31 million yuan in the previous year [10] - Jiahe Meikang forecasts a loss of 240 million to 280 million yuan for 2025, compared to a loss of 256 million yuan in the previous year [11] - Light Textile City expects a loss of 15 million to 22.5 million yuan for 2025 [23] - Ailon Technology anticipates a profit of 14.96 million to 22.44 million yuan for 2025, reversing a loss of 21.70 million yuan from the previous year [24] - ST Yun Chuang forecasts a loss of 139 million to 149 million yuan for 2025, with projected revenue of 53.5 million to 57.5 million yuan, a year-on-year increase of 6.15% to 14.09% [42] - Meike Home expects a loss of 1.2 billion to 1.8 billion yuan for 2025, compared to a loss of 864 million yuan in the previous year [36] Group 3: Shareholder Actions - Huafeng Chemical announced that shareholders plan to reduce their holdings by no more than 0.73% of the company's shares [8] - Naxinwei disclosed that shareholders plan to reduce their holdings by no more than 1.75% of the company's shares [12] - Shikong Technology announced that a shareholder plans to reduce their holdings by no more than 3% of the company's shares [13] - Yandong Micro disclosed that a shareholder plans to reduce their holdings by no more than 1% of the company's shares [37] - Daily Interaction announced that shareholders plan to reduce their holdings by no more than 0.135% of the company's shares [41]

览富财经网讯：1月29日，仙乐健康科技股份有限公司（简称：仙乐健康，300791.SZ）递表港交所主 板，中信证券为其独家保荐人。 据了解，仙乐健康是领先的营养健康食品解决方案供应商，公司在2024年全球营养健康食品解决方案市 场中按收入计排名第三，并在中国营养健康食品解决方案市场中位居第一。此外，按2024年的收入计， 亦为全球第二大以软糖及软胶囊为基础的营养健康食品解决方案供应商。立足于潜力巨大的营养健康食 品解决方案市场，公司的业务表现实现稳健增长并保持可持续发展。仙乐健康作为营养健康食品解决方 案市场的先驱，已建立全球业务布局，拥有全球整合且于本地快速响应的生产基地、研发中心及供应链 体系网络。强大的研发与供应链能力，结合全球资源支撑的卓越营运效率，使公司能够持续为全球客户 提供端到端的解决方案，涵盖市场洞察、定制化解决方案、差异化研发、全球生产能力、全行业协作及 营销赋能。 财务资料： 根据招股书披露显示，于往绩记录期间，仙乐健康的收入及毛利录得强劲增长。收入由2023年的人民币 3,582.0百万元增加17.6%至2024年的人民币4,211.1百万元。收入亦由截至 2024年9月30日止九个月的 ...

Investment Rating - The report assigns an "Accumulate" rating to the probiotic industry, highlighting its high growth potential and the emerging opportunities within the AKK strain segment [5]. Core Insights - The probiotic industry is projected to grow at a compound annual growth rate (CAGR) of 14.2% from 2023 to 2025, driven primarily by price increases rather than volume growth, with average price growth at 11.3% and volume growth at 2.4% [2]. - The AKK probiotic strain is expected to experience significant growth opportunities, particularly in areas such as metabolic health, immune health, and anti-aging, as consumer needs become more specific [2][5]. - Companies like Xianle Health, Junyao Health, and Beijia Clean are identified as key players to watch due to their innovative products and market strategies [5]. Summary by Sections Probiotic Industry Overview - The probiotic industry is characterized by double-digit growth, with strong efficacy and product combinations driving price increases [2]. - The market is seeing a shift towards products that address specific consumer pain points, such as sleep and immune enhancement [2]. Key Companies - **Xianle Health**: Launched its first self-developed probiotic, AKK ONE, which received GRAS certification, enhancing its market position in weight management and metabolic health [3]. - **Junyao Health**: Offers high-quality AKK strains with optimized production processes, achieving significant improvements in production efficiency and product quality [4]. - **Beijia Clean**: Acquired a stake in Shanen Kang, leveraging its early mover advantage in the AKK strain market with a robust patent portfolio [5]. Market Dynamics - The report emphasizes the increasing competition in the probiotic sector, with a focus on the AKK strain's potential to meet growing consumer demands for health benefits [5]. - The report notes that the AKK strain's sales on major e-commerce platforms are expected to rise significantly, indicating a burgeoning market opportunity [2].

Company Overview - Xianle Health Technology Co., Ltd. is a leading provider of nutritional health food solutions, holding the third-largest market share globally and the largest in China as of 2024 [2] - The company has transitioned its strategic focus from pharmaceuticals to nutritional health foods since its establishment in 1993, developing a comprehensive solution portfolio that caters to various demographics and product forms [2][4] - Xianle Health is recognized as a pioneer in establishing a global business layout in the nutritional health food solutions market, supported by a robust production and R&D network [2][5] Product Offerings - The company offers a wide range of products that address health needs across all age groups, including pregnant women, infants, children, adolescents, and the elderly [4] - It provides various product forms, including soft capsules, gummies, beverages, tablets, powders, and hard capsules, and is innovating to meet diverse market preferences [5][15] Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 was approximately CNY 3.582 billion, CNY 4.211 billion, and CNY 3.291 billion, respectively [6] - Profit for the same periods was approximately CNY 240 million, CNY 282 million, and CNY 55.5 million [7] - The gross profit margin has shown a steady increase, with rates of 29.7%, 30.6%, and 31.5% for the respective years [8] Industry Insights - The global nutritional health food market is projected to grow from USD 190 billion in 2024 to USD 249 billion by 2029, with a compound annual growth rate (CAGR) of approximately 5.6% [11] - The nutritional health food solutions market is expected to expand from USD 21.2 billion in 2020 to USD 29.4 billion in 2024, with a CAGR of 8.5% [12] - The market for gummy nutritional health food solutions is anticipated to grow from USD 2.4 billion in 2020 to USD 3.8 billion in 2024, reflecting a CAGR of 10.3% [15]

Company Overview - Xianle Health Technology Co., Ltd. is a leading provider of nutritional health food solutions, holding the third-largest market share globally in the nutritional health food solutions market as of 2024, and ranking first in China [4] - The company was established in 1993 and has shifted its strategic focus from pharmaceuticals to nutritional health foods, developing a comprehensive solution portfolio that covers a wide range of products for all demographics [4][5] - Xianle Health has established a global business layout with integrated production bases, R&D centers, and supply chain networks, enabling it to provide end-to-end solutions to clients worldwide [4][7] Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 was approximately CNY 3.582 billion, CNY 4.211 billion, and CNY 3.291 billion, respectively [8][11] - Profit for the same periods was approximately CNY 240 million, CNY 282 million, and CNY 55.5 million [9][11] - Gross profit margins for these periods were 29.7%, 30.6%, and 31.5%, indicating a steady increase in profitability [10][11] Industry Insights - The global nutritional health food market is projected to grow from USD 190 billion in 2024 to USD 249 billion by 2029, with a compound annual growth rate (CAGR) of approximately 5.6% [12] - The nutritional health food solutions market has seen significant growth, with revenue increasing from USD 21.2 billion in 2020 to USD 29.4 billion in 2024, and expected to reach USD 42.4 billion by 2029, reflecting a CAGR of 8.5% [15] - There is a growing trend towards diverse dosage forms in nutritional health foods, with gummies and soft capsules gaining popularity due to their convenience and consumer appeal [17]

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2026-020 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 仙乐健康科技股份有限公司 关于向香港联交所递交境外上市股份（H 股） 发行上市申请并刊发申请资料的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 1 https://www1.hkexnews.hk/app/sehk/2026/108162/documents/sehk26012901586. pdf 需要特别予以说明的是，本公告仅为境内投资者及时了解本次发行并上市的 相关信息而作出。本公告以及本公司刊登于香港联交所网站的申请资料均不构成 也不得视作对任何个人或实体收购、购买或认购公司本次发行的境外上市股份 （H 股）的要约或要约邀请。 公司本次发行并上市尚需取得中国证券监督管理委员会、香港证监会和香港 联交所等相关政府机关、监管机构、证券交易所的备案、批准和/或核准，该事 项仍存在不确定性。公司将根据本次发行并上市的后续进展情况依法及时履行信 息披露义务，敬请广大投 ...

据招股书，该公司成立于1993年，随着对健康需求的深入理解，该公司的战略重心逐步由制药转向营养 健康食品领域，并在过去33年的蓬勃发展中，该公司已建立全面的解决方案组合，覆盖全人群的全品类 多剂型产品体系，并得到跨多种业务模式的多元化客户群的支持。 据港交所1月29日披露，仙乐健康科技股份有限公司(简称：仙乐健康，300791.SZ)向港交所主板递交上 市申请书，中信证券为其独家保荐人。该公司是领先的营养健康食品解决方案提供商，根据灼识咨询数 据按2024年的收入计，该公司于全球营养健康食品解决方案市场占据第三大市场份额，而在中国营养健 康食品解决方案市场则排名第一。此外，根据灼识咨询的资料，按2024年收入计，该公司位列全球第二 大的软糖及软胶囊营养健康食品解决方案提供商。 ...